Mammoth Biosciences Receives FDA Emergency Use Authorization for First CRISPR-based High-Throughput COVID-19 Test

Mammoth Biosciences Receives FDA Emergency Use Authorization for First CRISPR-based High-Throughput COVID-19 Test

Business Wire

Published

BRISBANE, Calif.--(BUSINESS WIRE)-- #COVID--Mammoth Biosciences receives emergency use authorization from the FDA for the first CRISPR-based high-throughput COVID-19 test.

Full Article